BioWorld

May 6, 2008

FDA: Wider Use of Fentora Could Mean More Abuse

The FDA said that broader use of Cephalon Inc.'s narcotic pain drug Fentora (fentanyl buccal tablet) could lead to widespread abuse and misuse, with potentially fatal outcomes. (BioWorld Today) Read More

VaxGen Sells Anthrax Vaccine to Emergent for Potential $10M

EGF Receptor Helps Cancer Cells Independently of Kinase

Anavex Tackles AD Focusing On Causes, Not Symptoms

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for Dec. 11, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 11, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

DEE-lightful: Praxis’ phase II results allow stock to flex its muscle

BioWorld

Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...